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Eﬀects of bidi smoking on all-cause mortality and
cardiorespiratory outcomes in men from south Asia:
an observational community-based substudy of the
Prospective Urban Rural Epidemiology Study (PURE)
MyLinh Duong, Sumathy Rangarajan, Xiaohe Zhang, Kieran Killian, Prem Mony, Sumathi Swaminathan,
Ankalmadagu Venkatsubbareddy Bharathi, Sanjeev Nair, Krishnapillai Vijayakumar, Indu Mohan, Rajeev Gupta, Deepa Mohan, Shanthi Rani,
Viswanathan Mohan, Romaina Iqbal, Khawar Kazmi, Omar Rahman, Rita Yusuf, Lakshmi Venkata Maha Pinnaka, Rajesh Kumar,
Paul O’Byrne, Salim Yusuf

Summary
Background Bidis are minimally regulated, inexpensive, hand-rolled tobacco products smoked in south Asia. We
examined the eﬀects of bidi smoking on baseline respiratory impairment, and prospectively collected data for all-cause
mortality and cardiorespiratory events in men from this region.
Methods This substudy of the international, community-based Prospective Urban Rural Epidemiology (PURE) study
was done in seven centres in India, Pakistan, and Bangladesh. Men aged 35–70 years completed spirometry testing
and standardised questionnaires at baseline and were followed up yearly. We used multilevel regression to compare
cross-sectional baseline cardiorespiratory symptoms, spirometry measurements, and follow-up events (all-cause
mortality, cardiovascular events, respiratory events) adjusted for socioeconomic status and baseline risk factors
between non-smokers, light smokers of bidis or cigarettes (≤10 pack-years), heavy smokers of cigarettes only (>10 packyears), and heavy smokers of bidis (>10 pack-years).
Findings 14 919 men from 158 communities were included in this substudy (8438 non-smokers, 3321 light smokers,
959 heavy cigarette smokers, and 2201 heavy bidi smokers). Mean duration of follow-up was 5·6 years (range 1–13).
The adjusted prevalence of self-reported chronic wheeze, cough or sputum, dyspnoea, and chest pain at baseline
increased across the categories of non-smokers, light smokers, heavy cigarette smokers, and heavy bidi smokers
(p<0·0001 for association). Adjusted cross-sectional age-related changes in forced expiratory volume in 1 s (FEV1)
and FEV1/forced vital capacity (FVC) ratio were larger for heavy bidi smokers than for the other smoking categories.
Hazard ratios (relative to non-smokers) showed increasing hazards for all-cause mortality (light smokers 1·28
[95% CI 1·02–1·62], heavy cigarette smokers 1·59 [1·13–2·24], heavy bidi smokers 1·56 [1·22–1·98]), cardiovascular
events (1·45 [1·13–1·84], 1·47 [1·05–2·06], 1·55 [1·17–2·06], respectively) and respiratory events (1·30 [0·91–1·85],
1·21 [0·70–2·07], 1·73 [1·23–2·45], respectively) across the smoking categories.
Interpretation Bidi smoking is associated with severe baseline respiratory impairment, all-cause mortality, and
cardiorespiratory outcomes. Stricter controls and regulation of bidis are needed to reduce the tobacco-related disease
burden in south Asia.
Funding Population Health Research Institute, Canadian Institutes of Health Research, and Heart and Stroke
Foundation of Ontario.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license.

Introduction
Tobacco use is the world’s leading preventable cause of
premature death.1 The harmful eﬀects of cigarette
smoking have been extensively studied and are
universally accepted. Less is known about the health
eﬀects of non-cigarette tobacco products, such as bidis
(also known as beedis), which are commonly used in
populations of low socioeconomic status.
Bidis are inexpensive, small, hand-rolled tobacco
products commonly smoked in south Asia. Estimates
suggest that there were 53 million users of bidis in India
www.thelancet.com/lancetgh Vol 5 February 2017

and Bangladesh in 2003–09.2 Outside this region, bidi use
has mainly been reported in young adults in developed
countries,3 where unregulated marketing over the
internet and in ethnic stores has allowed easy access to
this vulnerable population. Bidis are manufactured in
south Asia by a cottage industry that has avoided many of
the local and international tobacco regulations and taxes
enforced on factory-made cigarettes. Consequently, bidis
are sold cheaply, at various prices and in packaging with
poorly visible health warnings.4–6 Furthermore, herbal and
ﬂavoured varieties are made to appeal to young adults as
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Research in context
Evidence before this study
We searched PubMed, Embase, the Cochrane database, and
bibliographies of retrieved articles for relevant reports published
in English between Jan 1, 1960, and Jan 1, 2016. We used
key search terms “beedi”, “beedis”, “bidi”, “bidis”,
“tobacco-smoking”, and “India”, “south Asia” to identify reports
of bidi smoking on health outcomes including mortality,
cardiorespiratory health, and lung function in south Asia. We
found few reports published after 2000. Previous publications
were not methodologically robust, and reported data derived
from retrospective, cross-sectional, or case-control studies with
limited and variable adjustments for potential confounders such
as diﬀerences in socioeconomic and baseline risk factors.
Furthermore, very few studies directly compared the eﬀects of
bidi smoking with cigarette smoking on cardiorespiratory
outcomes and lung function.
Added value of this study
To our knowledge, this is the largest prospective multisite
study with standardised approaches for data collection

“natural and safe” tobacco alternatives to cigarettes.3 This
claim contrasts with the toxicology data, which have
shown higher nicotine, tar, and carbon monoxide levels
delivered for a lower content of tobacco in bidis than in
cigarettes.7 However, there is a paucity of clinical data on
the health eﬀects of bidis. Most of these data are derived
from retrospective, cross-sectional, or case-control
studies, most with small sample sizes and limited
adjustments for a wide range of potential confounders.8–11
We prospectively assessed the eﬀects of bidi and
cigarette smoking on mortality, respiratory, and
cardiovascular outcomes in an unselected communitybased cohort of men in south Asia. All comparisons
were adjusted for diﬀerences in socioeconomic status,
user-speciﬁc characteristics, and baseline risk factors.
Furthermore, cross-sectional comparisons of selfreported baseline respiratory symptoms and spirometry
measurements were done to provide information about
baseline respiratory morbidity. The high prevalence of
low-intensity smoking (ie, ≤10 pack-years) in this cohort
provided an opportunity to assess the eﬀects of lowintensity tobacco smoking on health outcomes.

(covariates, cardiorespiratory symptoms, and lung function
measurements) and ascertainment of follow-up outcomes
(deaths and cardiorespiratory events) in India, Bangladesh,
and Pakistan. We examined the eﬀects of cigarette and bidi
smoking on several outcomes, adjusting for important
diﬀerences in socioeconomic and baseline risk factors. A
coherent pattern of worst outcomes was seen for bidi
smokers, including highest self-reported baseline respiratory
symptoms, obstructive ventilatory impairment, and
follow-up mortality and cardiorespiratory events compared
with cigarette smokers and non-smokers.
Implications of all the available evidence
Our ﬁndings ﬁll an important gap in knowledge about the
many harmful health eﬀects of bidi smoking. These ﬁndings
can be used for evidence-based practice and policy making
that will help bring about greater controls on bidi use in
south Asia.

environments, balanced by the feasibility of centres to
achieve long-term follow-up. Standardised approaches
were used for the enumeration of households,
identiﬁcation of individuals, recruitment, and data
collection. The methods of approaching households
diﬀered between countries, but aimed to avoid biases in
participant selection. Households with at least one
member aged 35–70 years who were intending to stay
locally for more than 4 years were approached. The ﬁnal
sample size for analysis varied by the outcome of interest
and included only men with no missing data relevant for
the outcome of interest. Only men were selected because
the rate of smoking in women in south Asia were low.
Similarly, former and current smokers were combined as
ever-smokers for all analyses.
All eligible individuals who provided written informed
consent were enrolled. Baseline data were collected from
Jan 1, 2003, to Dec 30, 2009, and follow-up data from
Jan 1, 2008, to Dec 30, 2013. The study was coordinated
by the Population Health Research Institute (Hamilton,
ON, Canada) and approved by the Hamilton Health
Sciences Research Ethics Board and by the local ethics
committee at each site.

Methods

See Online for appendix
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Study design and participants

Procedures

This substudy of the Prospective Urban Rural
Epidemiology (PURE) study included community-based
participants from India (ﬁve centres), Pakistan (one
centre), and Bangladesh (one centre). Details of the
overall PURE study design have been described
elsewhere12 and are summarised in the appendix (pp 5–9).
The centres were purposely chosen to provide a diverse
range of economic, physical, and sociocultural

Standardised interview-based questionnaires adapted
from previous cohort studies (appendix p 10) were
administered by trained personnel to household
members aged 35–70 years. The questionnaire elicited
demographic, household, behavioural, and medical
information (risk factors, symptoms, comorbid
disorders). Bidi and cigarette use was deﬁned as selfreported duration of use more than 0 days or quantity
www.thelancet.com/lancetgh Vol 5 February 2017
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more than none per day. Former smokers were deﬁned
as individuals who had not smoked for at least
12 months. Participants were classiﬁed into four
categories based on the number of pack-years of
smoking (duration [years] × quantity [sticks per day]
divided by 20) and tobacco type: non-smokers of bidis
or cigarettes (never-smokers), light smokers of either or
both products (≤10 pack-years), heavy smokers of
cigarettes only (>10 pack-years), and heavy smokers of
bidis (including concurrent use of cigarettes; >10 packyears). Other relevant data included cooking fuel (solid
or kerosene vs gas or electricity), education, asset index,
proportion of income spent on food, physical activity,
dietary intake, and cardiorespiratory symptoms
(dyspnoea with usual activity; wheeze; cough or
sputum; chest pain) occurring at least weekly in the
previous 6 months.
Household owned items were used to generate an asset
index, an indicator of wealth. Physical activity was
assessed with the International Physical Activity
Questionnaire (IPAQ).13 Dietary intake was assessed with
a validated food frequency questionnaire.14 Physical
measurements were collected by standardised methods

for anthropometrics, blood pressure, handgrip strength,
and spirometry. An individualised INTERHEART risk
score was calculated with the version excluding
cholesterol concentration. This score provided a validated
and quantitative measure of the risk-factor burden for
cardiovascular disease, which incorporates information
about self-reported age, sex, cigarette use, diabetes,
family history of cardiovascular disease, psychosocial
factors, diet, physical activity, and measured waist-to-hip
ratio and hypertension (≥140/90 mm Hg).15
Lung function was measured with a portable spirometer
(MicroGP, MicroMedical Ltd, Chatham, IL, USA), which
did not generate spirograms. Each participant attempted
up to six forced prebronchodilator manoeuvres while
standing and wearing a nose clip. Each manoeuvre was
closely observed for maximal eﬀort, with exhalation time
6 s or more and without coughing. Spirometers were
calibrated monthly (3 L syringe) or before each use in
extreme temperature or handling. For analyses, we
selected participants with at least two forced expiratory
volume in 1 s (FEV1) and forced vital capacity (FVC)
measurements within 200 mL variability. The quality of
the spirometry data in PURE have previously been

160 405 participants enrolled in PURE study

126 523 from outside south Asia excluded

33 882 from south Asia

18 915 women excluded because of low smoking rate

14 967 men

48 excluded because of missing data for smoking

14 919 included in substudy
8438 non-smokers
6481 smokers
3321 ≤10 pack-years of smoking
3160 >10 pack-years of smoking

2878 excluded because of absent or
poor-quality lung function data*

12 041 included in analysis of baseline lung
function

1655 excluded
217 missing follow-up data
1438 presence of self-reported
chronic diseases at baseline†

14 919 included in analysis of baseline
cardiorespiratory symptoms

13 264 included in analysis of follow-up events
(all-cause mortality, cardiovascular
events, respiratory events)

Figure 1: Participant selection for the substudy
PURE=Prospective Urban Rural Epidemiology Study. *Participants with poor-quality lung function data were those with less than two measurements of forced
expiratory volume in 1 s (FEV1) or forced vital capacity (FVC), or with variability between two the highest FEV1 or FVC measurements of >200 mL. †Participants with
self-reported diagnoses of cardiorespiratory disease, stroke, cancer, tuberculosis, or HIV infection at baseline were excluded from the analysis of follow-up events.
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validated for external, internal, and face validity (appendix
pp 11–16).16 The highest FEV1, FVC, and FEV1/FVC ratio
recorded for each individual was included in the analysis.
Participants were followed up with yearly telephone
calls and face-to-face interviews every 3 years. At each
contact, participants, or close relatives in cases of deaths
(via verbal autopsy17), were questioned as to whether any
clinical events had occurred and if so, documentation
was obtained for event adjudication by the site
investigators using standard deﬁnitions (appendix
pp 17–20). Furthermore, a random subset of events from
each site was assessed centrally (Population Health
Research Institute) to ensure consistency in the
adjudicated events.
To ensure standardisation and data quality, comprehensive operations manuals, reinforced by periodic
training workshops, training DVDs, and regular
communication were used in all sites. Data were entered
locally by each site into a customised database programmed
Non-smokers
(n=8438)

Light smokers
(n=3321)

Heavy cigarette
smokers
(n=959)

959 (100%)

Heavy bidi
smokers
(n=2201)

Tobacco type
Cigarettes only

··

1811 (55%)

Bidis only

··

1330 (40%)

··

180 (5%)

Both
Smokeless tobacco use*
Age (years)
Height (cm)

696 (8%)
49·3 (10·6)
164·9 (7·4)

227 (7%)
47·9 (10·0)
165·1 (7·2)

0

0

1627 (74%)

0

574 (26%)

57 (6%)
53·0 (9·1)
165·4 (6·9)

121 (5%)
51·9 (10·1)
164·2 (6·7)

Weight (kg)

63·6 (13·7)

59·8 (13·4)

63·2 (13·6)

Body-mass index (kg/m²)

23·4 (4·4)

22·0 (4·3)

23·0 (3·9)

20·2 (3·5)

4649 (55%)

1414 (43%)

578 (60%)

504 (23%)

Secondary or higher

5595 (67%)

1836 (56%)

633 (66%)

615 (28%)

Primary or none

2695 (33%)

1456 (44%)

321 (34%)

1573 (72%)

148 (2%)

29 (1%)

5 (1%)

13 (1%)

Urban residency

54·0 (10·8)

Education

Missing data
Asset index†

–0·8 (1·0)

–1·3 (0·8)

–0·7 (0·7)

–1·5 (0·5)

Proportion of income spent
on food (%)‡

54·3% (26·2)

62·3% (25·0)

58·5% (23·1)

68·3% (22·4)

Cooking fuel
Gas or electricity

4735 (61%)

1338 (43%)

583 (62%)

394 (21%)

Kerosene or solid fuel

3021 (39%)

1751 (57%)

353 (38%)

1502 (79%)

Missing data
Manual labour occupations§

682 (8%)
2267/8438
(45%)

232 (7%)
987/3321 (63%)

23 (2%)

305 (14%)

421/959 (60%)

1114/ (87%)

238 (11%)

Location¶
Bangladesh

572 (7%)

312 (9%)

211 (22%)

Chandigarh, India

1392 (16%)

89 (3%)

18 (2%)

127 (6%)

Chennai, India

1265 (15%)

473 (14%)

116 (12%)

306 (14%)

985 (12%)

549 (17%)

309 (32%)

228 (10%)

Bengaluru, India

2487 (29%)

1426 (43%)

146 (15%)

792 (36%)

Jaipur, India

1190 (14%)

344 (10%)

13 (1%)

507 (23%)

547 (6%)

128 (4%)

146 (15%)

Thiruvananthapuram,
India

Pakistan

3 (<1%)

(Table 1 continues on next page)
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with range and consistency checks and transmitted
electronically to the coordinating centre, where further
quality control measures were implemented.

Statistical analysis
We used multilevel marginal regression to estimate the
eﬀect size by smoking category on outcomes relative to
non-smokers adjusted for age, body-mass index, asset
index, education, cooking fuel, INTERHEART risk score,
diabetes, hypertension, and centre (except for spirometry
measurements and respiratory events). Community was
treated as a random eﬀect to account for data clustering.
Logistic regression provided estimates on the adjusted
prevalence and odds ratios (ORs) for cross-sectional
baseline symptoms. We used linear regression to compare
the cross-sectional age-related changes on baseline FEV1
and FEV1/FVC ratio by smoking category adjusted for
height, weight, centre, and education (FEV1) or age, height,
and centre (FEV1/FVC ratio). We used Cox proportional
hazards models to estimate the incidences and hazard
ratios (HRs) for all-cause mortality and cardiovascular
events (myocardial infarction, stroke, heart failure, sudden
death, cardiovascular-related death, and cardiovascularrelated hospital admission). For respiratory events (chronic
obstructive pulmonary disease, asthma, pneumonia,
tuberculosis), the same Cox model was used but without
INTERHEART risk score, diabetes, and hypertension as
covariates. To compare the eﬀect size estimates by smoking
category, smoking category was ﬁtted as a categorical
variable and its coeﬃcient reﬂects the nature of association
between eﬀect size and smoking category.
There was no formal sample size calculation for this
substudy. We assessed the adequacy of the sample size
using guidelines proposed by Concato and colleagues,18
which recommend that for Cox regression at least
ten events for each degree of freedom (df) are needed to
provide stable models. There were 685 deaths,
552 cardiovascular events, and 269 respiratory events
recorded during follow-up. The model for deaths and
cardiovascular events contained nine covariates including
the smoking categories, giving a total of 22 df. For the
respiratory event model, there were ﬁve covariates giving
a total of 16 df. Thus the events per df for mortality,
cardiovascular, and respiratory events were 31 (685/22),
25 (552/22), and 16 (269/16), respectively. These estimates
are all greater than ten events per df, indicating the
sample size was adequate to provide stable models for all
three event outcomes.
Some sensitivity analyses were carried out to examine
for any changes to our main ﬁndings on outcome events
using diﬀerent criteria for selection of study population
(including participants with signiﬁcant baseline
comorbidities); classiﬁcation of smoking categories
(excluding former smokers or smokers of both bidis and
cigarettes) and using diﬀerent socioeconomic status
covariates (education, rural or urban location, percent
income spent of food, and the combination of these). All
www.thelancet.com/lancetgh Vol 5 February 2017
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analyses were done with SAS version 9.2. No adjustments
for multiplicity of analysis were made.

Role of the funding source
The funders of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of
the report. The corresponding author had full access to all
the data in the study and had ﬁnal responsibility for the
decision to submit for publication.

Results
14 919 men from 158 communities across seven centres in
south Asia were included in this substudy (ﬁgure 1). Bidi
smoking was more common in India, whereas cigarette
smoking was more common in Bangladesh and Pakistan
(table 1). A small proportion of smokers reported using
both tobacco types; bidis were the predominant type. The
demographics of participants who smoked both bidis and
cigarettes were similar to the demographics of those who
smoked bidis only; we therefore reclassiﬁed this group as
bidi smokers (appendix p 21). A small and similar
proportion of participants across the smoking categories
reported the use of smokeless tobacco. There was a small
proportion of former smokers and the numbers were
evenly distributed across the smoking categories. Overall,
heavy bidi smokers were more likely to come from rural
communities and have a low socioeconomic status than
were men in all other smoking categories (lower
education and asset index; higher percentages of income
spent on food, manual labour occupations, and use of
solid or kerosene cooking fuels).
The adjusted prevalence of self-reported chronic
cardiorespiratory symptoms at baseline was signiﬁcantly
higher in heavy cigarette smokers and heavy bidi smokers
than in non-smokers (table 2, ﬁgure 2). The largest eﬀect
was seen for chronic cough and sputum. Light smokers
showed a modest increase in adjusted prevalence of
chronic symptoms relative to non-smokers; however,
because of low reported rates of wheeze and dyspnoea,
the increase in these symptoms was not signiﬁcant. The
prevalence of chronic symptoms at baseline increased
across the categories of non-smokers, light smokers,
heavy cigarette smokers, and heavy bidi smokers
(p<0·001 for association).
For the cross-sectional analysis of spirometry measurements, centres from Pakistan, Jaipur (India), and
Bangladesh were excluded because of high proportions of
participants with missing spirometry data (ﬁgure 1). We
therefore examined spirometry data from the ﬁve centres
in India. The adjusted cross-sectional age-related changes
in FEV1 and FEV1/FVC ratio were signiﬁcantly larger for
heavy bidi smokers than for men in the other smoking
categories (table 3, ﬁgure 3). This ﬁnding suggests
increasingly lower lung function in the older age groups of
bidi smokers. By contrast, age-related changes in FEV1 did
not diﬀer between non-smokers, light smokers, and heavy
cigarette smokers. However, similar pairwise comparison
www.thelancet.com/lancetgh Vol 5 February 2017

Non-smokers
(n=8438)

Light smokers
(n=3321)

Heavy cigarette
smokers
(n=959)

Heavy bidi
smokers
(n=2201)

(Continued from previous page)
Smoking history
Age of smoking initiation
(years)

··

31·0 (11·6)

22·7 (8·4)

22·7 (9·1)

Duration of smoking
(years)

··

15·7 (10·6)

29·2 (10·1)

28·7 (11·0)

Tobacco sticks smoked
per day

··

6·1 (5·0)

18·2 (13·6)

21·0 (11·7)

Tobacco stick-years¶

··

83·0 (61·4)

494·3 (378·6)

575·4 (393·3)

Pack-years||

··

4·2 (3·1)

24·7 (18·9)

Current smokers**

··

2934 (88%)

807 (84%)

1995 (91%)

Former smokers

··

364 (11%)

145 (15%)

192 (9%)

Missing data

··

23 (1%)

7 (1%)

14 (1%)

28·8 (19·7)

Data are n (%) or mean (SD). Non-smokers self-reported no bidi or cigarette use at baseline survey; light smokers
reported smoking ten or fewer pack-years of either bidis, cigarettes, or both; and heavy smokers (>10 pack-years) are
divided into those who smoked cigarettes only and those who smoked bidis with or without cigarettes. ··=not
applicable. *Smokeless tobacco use was deﬁned as self-reported duration of use more than 0 days or quantity more
than none per day of smokeless tobacco (chewed tobacco, snuﬀ, or rolled tobacco leaves). †Asset index is the nonmonetary aspect of wealth based on the number and type of household items owned (a high positive value indicates
greater wealth). ‡Lower-income families spend a greater percentage of total income on food. §Manual labour includes
workers in agricultural, ﬁshery, and craft industries, plant/machine operators, assemblers, and elementary workers;
missing data mainly due to retirement. ¶Tobacco stick-years=number of tobacco sticks smoked per day × duration of
smoking (years). ||Pack-years=tobacco stick-years/20. **Current smokers were deﬁned as individuals who reported use
of at least one tobacco stick per day within 12 months.

Table 1: Baseline characteristics

showed a signiﬁcantly reduced FEV1/FVC ratio, suggesting
mild obstructive ventilatory impairment, in light smokers
and heavy cigarette smokers compared with non-smokers.
Mean duration of follow-up was 5·6 years (range 1–13).
13 264 (98%) participants completed follow-up, with a
similar proportion in each smoking category (7554 [98%]
non-smokers; 2966 [98%] light smokers; 819 [99%] heavy
cigarette smokers; 1925 [98%] heavy bidi smokers).
Participants with self-reported baseline cardiovascular
disease, respiratory disease, cancer, or HIV infection
were excluded from the analysis of follow-up events
(ﬁgure 1). The demographics of the excluded and
included participants were similar (appendix pp 21). In
the analysis population, there were 685 deaths,
552 cardiovascular events, and 269 respiratory events
(table 4). Heavy bidi smokers had the highest incidence
of follow-up events compared with men in the other
smoking categories (table 4, ﬁgure 4). The largest eﬀect
of heavy bidi smoking was on respiratory events. The
incidence of follow-up events in light smokers and heavy
cigarette smokers was intermediate between that for
non-smokers and heavy bidi smokers; however, the
increase in incidence of respiratory events in light
smokers and heavy cigarette smokers compared with
non-smokers was not signiﬁcant. The HRs for follow-up
events increased across the categories of light smokers,
heavy cigarette smokers, and heavy bidi smokers.
We did sensitivity analyses that included all participants
with complete vital statistics; adjusted for other indicators
e172
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Non-smokers (n=8438) Light smokers (n=3321)

Heavy cigarette smokers (n=959) Heavy bidi smokers (n=2201)

Wheeze
Number

425

234

69

242

Adjusted prevalence (95% CI)

4·3% (3·4–5·4)

5·1% (3·9–6·6)

6·1% (4·2–8·7)

Adjusted OR (95% CI)

1·0

1·20 (0·97–1·50)

1·45 (1·10–1·92)

0·092

0·009

p value

··

8·0% (6·2–10·2)
1·95 (1·59–2·39)
<0·0001

Cough or sputum
Number
Adjusted prevalence (95% CI)
Adjusted OR (95% CI)

1094

686

12·9% (11·0–15·2)
1·0

p value

··

214

696

17·9% (15·2–20·8)

21·4% (18·1–25·1)

1·46 (1·27–1·69)

1·83 (1·49–2·24)

26·7% (23·2–30·5)
2·45 (2·07–2·89)

0·0001

0·0001

0·0001

Dyspnoea with usual activity
Number
Adjusted prevalence (95% CI)
Adjusted OR (95% CI)

966

469

12·8% (11·4–14·3)
1·0

p value

··

170

508

15·0% (13·3–16·8)

19·7% (16·4–23·4)

1·20 (1·05–1·39)

1·67 (1·36–2·06)

0·010

<0·0001

19·6% (16·6–23·0)
1·67 (1·36–2·04)
<0·0001

Chest pain
Number
Adjusted prevalence (95% CI)
Adjusted OR (95% CI)
p value

1241

677

15·9% (14·5–17·5)
1·0
··

181

612

19·9% (17·9–22·1)

20·2% (17·5–23·1)

1·31 (1·16–1·48)

1·33 (1·09–1·63)

23·6% (20·9–26·5)
1·63 (1·40–1·89)

0·0001

0·006

0·0001

Self-reported baseline symptoms deﬁned as those occurring at least weekly in the 6 months before the baseline survey. ORs (relative to non-smokers) were estimated with
multilevel marginal logistic regression with age, asset index, body-mass index, and centre as covariates. Community was treated as a random eﬀect to account for data
clustering. OR=odds ratio.

Table 2: Self-reported cardiorespiratory symptoms at baseline

35

Adjusted prevalence (%)

30

Heavy bidi smokers
Heavy cigarette smokers
Light smokers
Non-smokers

25
20
15
10
5
0

p<0·0001 for association p<0·0001 for association p<0·0001 for association p<0·0001 for association
Wheeze

Cough or sputum

Dyspnoea

Chest pain

Figure 2: Self-reported cardiorespiratory symptoms at baseline
Self-reported baseline symptoms deﬁned as those occurring at least weekly in the 6 months before the baseline
survey. p value for association examined the order eﬀect in eﬀect size by diﬀerent smoking groups (as categorical
variable). Error bars represent 95% CI.

of socioeconomic status alone or in combination; and
excluded former smokers and smokers of both bidis and
cigarettes (appendix p 23–24). Results of sensitivity
analyses showed the conclusions remained unchanged.

Discussion
In this prospective community-based cohort study of
unselected men in south Asia, we recorded a high
prevalence of bidi and cigarette use. Bidi smokers were
more likely to be from rural areas and have low
socioeconomic status. Accounting for these diﬀerences
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and additional baseline risk factors, bidi use was
consistently associated with signiﬁcantly increased
prevalences and relative risks of baseline cardiorespiratory
symptoms, low ventilatory capacity, and follow-up
mortality and cardiorespiratory outcomes. Light smokers
and heavy cigarette smokers also showed increased risks
of death and cardiovascular events relative to nonsmokers, but not for respiratory events. The observed
pattern of greater baseline respiratory morbidity and
higher risks of mortality and cardiorespiratory outcomes
in heavy bidi smokers suggest that bidis are at least as
harmful as cigarettes and contribute to the burden of
tobacco-related disease and deaths in south Asia.
Our reported rates and pattern of bidi use are
consistent with previous data, indicating a high
prevalence of bidi smoking in south Asia, with
geographical19 and socioeconomic variation.20,21 These
baseline diﬀerences could potentially confound the
relation between bidi smoking and health outcomes.
Our large sample size and data on socioeconomic status
and other characteristics made it possible to adjust for a
large number of potentially important confounders, in
order to derive an unbiased estimate of the independent
eﬀect of bidi smoking on cardiorespiratory health and
mortality. In addition to the covariates included in the
ﬁnal model, we also explored other potential confounders
in several sensitivity analyses and found their eﬀects
were small and did not substantially change the overall
model or conclusions.
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Non-smokers (n=6701)

Light smokers (n=2849)

Heavy cigarette smokers
(n=800)

Heavy bidi smokers
(n=1691)

–22·1 (–23·8 to –20·4)

–22·5 (–24·2 to –20·8)

–22·7 (–24·7 to –20·8)

–23·8 (–25·6 to –22·0)

FEV1
Change per year, mL/s (95% CI)
Diﬀerence from non-smokers
p value

0
··

–0·3 (–0·9 to 0·2)

–0·6 (–1·5 to 0·3)

0·198

0·191

–1·7 (–2·3 to –1·0)
<0·0001

FEV1/FVC ratio
Change per year (95% CI)
Diﬀerence from non-smokers
p value

–0·145% (–0·171 to –0·119)
0
··

–0·160% (–0·184 to –0·136)

–0·158% (–0·184 to –0·132)

–0·180% (–0·207 to –0·153)

–0·015% (–0·027 to –0·003)

–0·013% (–0·028 to 0·002)

–0·035% (–0·049 to –0·022)

0·012

0·097

<0·0001

Multilevel marginal linear regression was used to estimate the cross-sectional age-related change in forced expiratory volume in 1 s (FEV1) or FEV1/forced vital capacity (FVC)
ratio by smoking category adjusted for height, weight, centre, and education (FEV1) or age, height, and centre (FEV1/FVC ratio). Community was treated as a random eﬀect.
Diﬀerences in the cross-sectional age-related change relative to non-smokers were also adjusted for the same covariates.

Table 3: Cross-sectional age-related changes in FEV1 and FEV1/FVC ratio
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Adjusted FEV1 by smoking category
Heavy bidi smokers
Heavy cigarette smokers
Light smokers
Non-smokers

2·6

Adjusted FEV1 (L/s)

2·4

2·2

2·0

1·8

1·6
Adjusted FEV1/FVC ratio by smoking category
93
92
91
Adjusted FEV1 /FVC ratio (%)

Few contemporary data exist about the respiratory
eﬀects of bidis. Early studies showed an association
between bidi smoking with chronic cough and sputum.22–25
In keeping with these ﬁndings, we noted that the
prevalence and risk of cardiorespiratory symptoms were
consistently higher in heavy bidi smokers than in men in
the other smoking categories; bidi smokers also had the
lowest adjusted ventilatory capacity. The ﬁnding for
ventilatory capacity had not been consistently documented
across earlier studies, which were limited by small sample
sizes and variability in their adjustments of potential
confounders.24,26,27 Our study is the largest study so far to
compare spirometry data between bidi and cigarette
smokers. Our ﬁndings suggest lower ventilatory capacity
and greater airﬂow obstruction in heavy bidi smokers, and
together with a higher prevalence of cardiorespiratory
symptoms indicate substantially higher rates of obstructive
respiratory impairment in bidi smokers compared with
other smokers. Heavy cigarette smokers and light smokers
also showed lower adjusted lung function than did nonsmokers, but the magnitude of this diﬀerence did not
reach signiﬁcance. This ﬁnding might relate to the smaller
sample size in these subgroups or the greater variability in
the eﬀect of cigarette smoking on lung function.
Large population-based studies have examined the
incidence of cancer, cardiovascular disease, and all-cause
mortality in tobacco users in south Asia.9,10,28–31 To our
knowledge, only one other publication has reported on
the eﬀect of bidis separately from cigarettes on all-cause
mortality (HR relative to never-smokers 1·64 [95% CI
1·47–1·81] for bidi smokers vs 1·37 [1·23–1·53] for
cigarette smokers).9 Our work supports and extends this
ﬁnding by showing that the risks of cardiorespiratory
events are also signiﬁcantly increased with bidi smoking
independent of socioeconomic status.
Several aspects of this study are worthy of discussion.
First, our study population included a large number of
light smokers, particularly of cigarettes. Separating out
the light smokers provided a more balanced and matched
distribution of smoking intensity and smoking pattern

90
89
88
87
86
85
84
83

35–43

44–53
54–63
Age range (years)

≥64

Figure 3: Mean adjusted FEV1 and FEV1/FVC ratio by age group
Multilevel marginal linear regression was used to model forced expiratory volume
in 1 s (FEV1) by age group and smoking category with height, weight, centre, and
education as covariates (reference: non-smokers) and community as a random
eﬀect. A similar model was used for the comparison of FEV1/forced vital capacity
(FVC) ratio by age group and smoking category with age, height, and centre as
covariates (reference: non-smokers) and community as a random eﬀect.

between heavy bidi smokers and heavy cigarette smokers
for comparison. We found that low-intensity smoking
can also be associated with respiratory impairment at an
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Heavy cigarette
smokers
(n=819)

Heavy bidi
smokers
(n=1925)

Non-smokers
(n=7554)

Light smokers
(n=2966)

Number

234

144

Adjusted incidence (95% CI)

3·1%
(2·4–3·9)

4·6%
(3·4–6·3)

4·4%
(3·0–6·3)

5·1%
(3·5–7·3)

1·0

1·45
(1·13–1·84)

1·47
(1·05–2·06)

1·55
(1·17–2·06)

··

0·003

0·023

0·002

Cardiovascular events

Adjusted HR (95% CI)
p value

65

109

Respiratory events
Number

99

Adjusted incidence (95% CI)

61

0·7%
(0·4–1·1)

Adjusted HR (95% CI)

27

82

0·9%
(0·6–1·5)

0·8%
(0·4–1·5)

1·3%
(0·8–2·2)

1·0

1·30
(0·91–1·85)

1·21
(0·70–2·07)

1·73
(1·23–2·45)

··

0·154

0·496

0·002

p value
Deaths
Number

279

165

Adjusted incidence (95% CI)

2·3%
(1·7–3·0)

3·1%
(2·1–4·5)

3·3%
(2·2–5·0)

3·8%
(2·7–5·5)

1·0

1·28
(1·02–1·62)

1·59
(1·13–2·24)

1·56
(1·22–1·98)

··

0·034

0·008

<0·0003

Adjusted HR (95% CI)
p value

58

183

New cardiovascular events (cardiovascular-related death, myocardial infarction, heart failure, stroke, and
cardiovascular-related hospital admission), respiratory events (chronic obstructive pulmonary disease [COPD],
pneumonia, tuberculosis, asthma), and all-cause mortality at a mean follow-up of 5·6 years. Incidence and HRs
(relative to non-smokers) for all-cause mortality and cardiovascular events were adjusted for age, body-mass index,
asset index, education, handgrip, INTERHEART risk score, diabetes, and hypertension, and centre as ﬁxed-eﬀect
covariates, and community as a random eﬀect in a multilevel marginal Cox proportional hazards model. For respiratory
events, the same model was used but without INTERHEART risk score, diabetes, and hypertension as covariates in the
model. HR=hazard ratio. *Participants with missing data or with self-reported diagnoses of stroke, heart disease,
cancer, COPD, asthma, tuberculosis, or HIV infection were excluded from the analysis.

Table 4: Respiratory events, cardiovascular events, and deaths during follow-up*

6

3

Heavy bidi smokers
Heavy cigarette smokers
Light smokers
Non-smokers

2
4
1
2

0

p=0·001 for association

p=0·003 for association

p=0·019 for association

Deaths

Cardiovascular events

Respiratory events

Adjusted incidence (%)
Respiratory events

Adjusted incidence (%)
Deaths and cardiovascular events

8

0

Figure 4: Respiratory events, cardiovascular events, and deaths during follow-up
New cardiovascular events (cardiovascular-related death, myocardial infarction, heart failure, stroke, and
cardiovascular-related hospital admission), respiratory events (chronic obstructive pulmonary disease, pneumonia,
tuberculosis, asthma), and all-cause mortality at a mean follow-up of 5·6 years. Hazard ratios (relative to
non-smokers) for all-cause mortality and cardiovascular events were estimated with a marginal Cox proportional
hazards model with age, education, asset index, body-mass index, handgrip, self-reported diabetes, hypertension,
INTERHEART risk score, and centre as ﬁxed eﬀects and community as a random eﬀect. For respiratory events, the
same model was used but without INTERHEART risk score, diabetes, and hypertension as covariates in the model.
p value for association examined the order eﬀect in eﬀect size by diﬀerent smoking groups (as categorical
variable). Error bars represent 95% CI.
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exposure level that is often considered to be clinically
trivial. Furthermore, this level of exposure was associated
with increased risks of cardiovascular events and
mortality compared with not smoking. This ﬁnding
suggests that there is no threshold that can be considered
safe from the harmful eﬀects of tobacco smoking.
Second, bidis are smaller with less tobacco content and
are generally sold in diﬀerent quantities from cigarettes.
These diﬀerences make comparison of the two tobacco
types using a common unit of exposure such as packyears diﬃcult. To maintain consistency and allow ease of
comparison with the literature on tobacco, we continued
to use pack-years to deﬁne the groups. However, any
interpretation of the eﬀect size of bidi use on outcomes
must take into account of the lower tobacco content in
bidis compared with cigarettes.7 Finally, only participants
with no previous cardiorespiratory morbidity, cancer, or
HIV infection were analysed for follow-up events to avoid
the eﬀect of reverse causality on our ﬁndings.
There are limitations and strengths to our study. It was
not feasible to aim for strict proportionate sampling in this
large prospective cohort study. The design did not use
standard random sampling but adopted a design that
avoided biases in levels of risk factors and prevalence of
disease conditions. Second, lung function was measured
with a portable spirometer that did not provide ﬂow-volume
curves and therefore veriﬁcation of individual eﬀort was
not possible. However, we had previously validated this
method by comparing data obtained in certiﬁed pulmonary
function laboratories with data obtained by PURE methods
for 531 participants from participating sites including south
Asia; we noted high correlations without biases.16 Further,
there is no a-priori reason to expect diﬀerential eﬀects in
methods on spirometry measurements between diﬀerent
smoking groups. The major strengths of our study include
the large sample size, the prospective and standardised
approach to data collection and outcome ascertainment, all
of which provide for a robust and systematic analysis, and
adjustment for a large number of potential confounders.
Our ﬁndings have important public health implications.
South Asia is the second largest consumer of tobacco in
the world, with more than 130 million tobacco smokers.2
More than half these smokers use bidis, particularly
among the poorest and most vulnerable sectors of the
population. Therefore the health impact of bidis is highly
relevant in this region. Furthermore, as the current trend
of bidi exportation continues, the global impact of bidis
will rise, particularly among young adults. Our ﬁndings
suggest that bidis are at least as harmful as cigarettes on
cardiorespiratory health and mortality, despite having
substantially less tobacco content than cigarettes. Control
of bidis should be an integral part of any anti-tobacco
framework, both regionally and globally, with the greatest
potential eﬀects to be seen in poor and young people.
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